Kallistatin as a marker of microvascular complications in children and adolescents with type 1 diabetes mellitus: Relation to carotid intima media thickness

Vascular Medicine (United Kingdom)

Volumn 20, Issue 6, 2015, Pages 509-517

  El Asrar, Mohamed A ^a   Andrawes, Nevine G ^a   Ismail, Eman A ^a   Salem, Shaimaa M H ^a  

^a AIN SHAMS UNIVERSITY   (Egypt)

Author keywords

adolescents; carotid intima media thickness; children; kallistatin; microvascular complications; type 1 diabetes

Indexed keywords

C REACTIVE PROTEIN; HEMOGLOBIN A1C; KALLISTATIN; SERINE PROTEINASE INHIBITOR; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; LIPID;

ADOLESCENT; ADULT; ARTERIAL WALL THICKNESS; ARTICLE; CHILD; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE DURATION; FEMALE; GLYCEMIC CONTROL; HUMAN; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; MICROALBUMINURIA; MICROANGIOPATHY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SCHOOL CHILD; SENSITIVITY AND SPECIFICITY; URINARY ALBUMIN CREATININE RATIO; ALBUMINURIA; ANALYSIS; BLOOD; CAROTID ARTERY DISEASES; CASE CONTROL STUDY; COMPARATIVE STUDY; COMPLICATION; DIABETES MELLITUS, TYPE 1; DIABETIC ANGIOPATHIES; GLUCOSE BLOOD LEVEL; MICROCIRCULATION; PATHOPHYSIOLOGY; PREDICTIVE VALUE;

ADOLESCENT; ALBUMINURIA; BIOMARKERS; BLOOD GLUCOSE; C-REACTIVE PROTEIN; CAROTID ARTERY DISEASES; CAROTID INTIMA-MEDIA THICKNESS; CASE-CONTROL STUDIES; CHILD; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 1; DIABETIC ANGIOPATHIES; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; LIPIDS; MALE; MICROCIRCULATION; PREDICTIVE VALUE OF TESTS; SERPINS;

EID: 84947935049     PISSN: 1358863X     EISSN: 14770377     Source Type: Journal    
DOI: 10.1177/1358863X15591089     Document Type: Article

References (56)

1. Nayak SB, Bhaktha G,. Relationship between sialic acid and metabolic variables in Indian type 2 diabetic patients. Lipids Health Dis 2005; 4: 15-19.
2. Vilbergsson S, Sigurdsson G, Sigvaldason H, Sigfusson N,. Coronary heart disease mortality amongst non-insulin-dependent diabetic subjects in Iceland: The independent effect of diabetes. The Reykjavik Study 17-year follow up. J Intern Med 1998; 244: 309-316.
3. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM,. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001; 286: 327-334.
4. Jenkins AJ, Best JD, Klein RL, Lyons TJ,. Lipoproteins, glycoxidation and diabetic angiopathy. Diabetes Metab Res Rev 2004; 20: 349-368.
5. Acerini CL,. Type 1 diabetes mellitus: Long-term complication. In: Tasker RC, McClure RJ, Acerini CL, (eds) Oxford Handbook of Pediatrics, 1st edition. Oxford: Oxford University Press, 2008, pp. 412-421.
6. Jenkins AJ, McBride JD, Januszewski AS, et al. Increased serum kallistatin levels in type 1 diabetes patients with vascular complications. J Angiogenes Res 2010; 2: 19.
7. Chao J, Chai KX, Chen LM, et al. Tissue kallikrein-bindingprotein is a serpin. I. Purification, characterization, and distribution in normotensive and spontaneously hypertensive rats. J Biol Chem 1990; 265: 16,394-16,401.
8. Miao RQ, Murakami H, Song Q, Chao L, Chao J,. Kallistatin stimulates vascular smooth muscle cell proliferation and migration in vitro and neointima formation in balloon-injured rat artery. Circ Res 2000; 86: 418-424.
9. Miao RQ, Agata J, Chao L, Chao J,. Kallistatin is a new inhibitor of angiogenesis and tumor growth. Blood 2002; 100: 3245-3252.
10. Chao J, Miao RQ, Chen V, Chen LM, Chao L,. Novel roles of kallistatin, a specific tissue kallikrein inhibitor, in vascular remodeling. Biol Chem 2001; 382: 15-21.
11. Gao L, Yin H, Smith RS Jr, Chao L, Chao J,. Role of kallistatin in prevention of cardiac remodeling after chronic myocardial infarction. Lab Invest 2008; 88: 1157-1166.
12. Shen B, Hagiwara M, Yao YY, Chao L, Chao J,. Salutary effect of kallistatin in salt-induced renal injury, inflammation, and fibrosis via antioxidative stress. Hypertension 2008; 51: 1358-1365.
13. Hatcher HC, Ma JX, Chao J, Chao L, Ottlecz A,. Kallikrein-binding protein levels are reduced in the retinas of streptozotocin-induced diabetic rats. Invest Ophthalmol Vis Sci 1997; 38: 658-664.
14. Hernández C, Simó R,. Strategies for blocking angiogenesis in diabetic retinopathy: From basic science to clinical practice. Expert Opin Investig Drugs 2007; 16: 1209-1226.
15. Shiau AL, Teo ML, Chen SY, et al. Inhibition of experimental lung metastasis by systemic lentiviral delivery of kallistatin. BMC Cancer 2010; 10: 245.
16. Kota SK, Mahapatra GB, Kota SK, et al. Carotid intima media thickness in type 2 diabetes mellitus with ischemic stroke. Indian J Endocrinol Metab 2013; 17: 716-722.
17. Gupta A, Yadav S, Gupta VK,. Carotid intimo-medial thickness [cIMT] and correlation to cardiac risk factors in adolescent type 1 diabetics. J Diabetes Endocrinol 2013; 4: 12-18.
18. Ravikumar R, Deepa R, Shanthirani C, Mohan V,. Comparison of carotid intima media thickness, arterial stiffness and brachial artery flow mediated dilation in diabetic and nondiabetic subjects (The Chenai Urban Population Study [CUPS-9]). Am J Cardiol 2002; 90: 702-707.
19. American Diabetes Association (ADA). Diagnosis and classification of diabetes mellitus. Diabetes Care 2010; 33 (Suppl 1): S62-S69.
20. Wilkinson CP, Ferris FL 3rd, Klein RE, et al. Global Diabetic Retinopathy Project Group. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology 2003; 110: 1677-1682.
21. Weintrob N, Amitay I, Lilos P, Shalitin S, Lazar L, Josefsberg Z,. Bedside neuropathy disability score compared to quantitative sensory testing for measurement of diabetic neuropathy in children, adolescents, and young adults with type 1 diabetes. J Diabetes Complications 2007; 21: 13-19.
22. England JD, Gronseth GS, Franklin G, et al. Distal symmetric polyneuropathy: A definition for clinical research: Report of the American Academy of Neurology, the American Association of Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology 2005; 64: 199-207.
23. Third Report of the National Cholesterol Education Program (NCEP). Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circulation 2002; 106: 3143-3421.
24. Cook S, Auinger P, Huang TT,. Growth curves for cardio-metabolic risk factors in children and adolescents. J Pediatr 2009; 155: S6-S26.
25. Tabaei BP, Al-Kassab AS, Ilag LL, Zawacki CM, Herman WH,. Does microalbuminuria predict diabetic nephropathy? Diabetes Care 2001; 24: 1560-1566.
26. Molitch ME, DeFronzo RA, Franz MJ, et al. American Diabetes Association. Nephropathy in diabetes. Diabetes Care 2004; 27: S79-S83.
27. Dalla Pozza R, Ehringer-Schetitska D, Fritsch P, Jokinen E, Petropoulos A, Oberhoffer R, Association for European Paediatric Cardiology Working Group Cardiovascular Prevention. Intima media thickness measurement in children: A statement from the Association for European Paediatric Cardiology (AEPC) Working Group on Cardiovascular Prevention endorsed by the Association for European Paediatric Cardiology. Atherosclerosis 2015; 238: 380-387.
28. Cohen-Bucay A, Viswanathan G,. Urinary markers of glomerular injury in diabetic nephropathy. Int J Nephrol 2012; 2012: 146987.
29. Maric C, Hall JE,. Obesity, metabolic syndrome and diabetic nephropathy. Contrib Nephrol 2011; 170: 28-35.
30. McBride JD, Jenkins AJ, Liu X, et al. Elevated circulation levels of an antiangiogenic SERPIN in patients with diabetic microvascular complications impair wound healing through suppression of Wnt signaling. J Invest Dermatol 2014; 134: 1725-1734.
31. Chao J, Schmaier A, Chen LM, Yang Z, Chao L,. Kallistatin, a novel human tissue kallikrein inhibitor: Levels in body fluids, blood cells, and tissues in health and disease. J Lab Clin Med 1996; 127: 612-620.
32. Idris I, Gray S, Donnelly R,. Protein kinase C-beta inhibition and diabetic microangiopathy: Effects on endothelial permeability responses in vitro. Eur J Pharmacol 2004; 485: 141-144.
33. Ferrara N,. Role of vascular endothelial growth factor in regulation of physiological angiogenesis. Am J Physiol Cell Physiol 2001; 280: C1358-C1366.
34. Kakizawa H, Itoh M, Itoh Y, et al. The relationship between glycemic control and plasma vascular endothelial growth factor and endothelin-1 concentration in diabetic patients. Metabolism 2004; 53: 550-555.
35. Schiekofer S, Balletshofer B, Andrassy M, Bierhaus A, Nawroth PP,. Endothelial dysfunction in diabetes mellitus. Semin Thromb Hemost 2000; 26: 503-511.
36. Forstermann U, Munzel T,. Endothelial nitric oxide synthase in vascular disease: From marvel to menace. Circulation 2006; 113: 1708-1714.
37. Cooke JP,. NO and angiogenesis. Atheroscler Suppl 2003; 4: 53-60.
38. Aoki M, Nata T, Morishita R, et al. Endothelial apoptosis induced by oxidative stress through activation of NF-Antiapoptotic effect of antioxidant agents on endothelial cells. Hypertension 2001; 38: 48-55.
39. Gustavsson C, Agardh E, Bengtsson B, Agardh C,. TNF-α is an independent serum marker for proliferative retinopathy in type 1 diabetic patients. J Diabetes Complications 2008; 2: 309-316.
40. Wolf WC, Harley RA, Sluce D, Chao L, Chao J,. Localization and expression of tissue kallikrein and kallistatin in human blood vessels. J Histochem Cytochem 1999; 47: 221-228.
41. Ferrara N, Alitalo K,. Clinical applications of angiogenic growth factors and their inhibitors. Nat Med 1999; 5: 1359-1364.
42. Ma JX, King LP, Yang Z, Crouch RK, Chao L, Chao J,. Kallistatin in human ocular tissues: Reduced levels in vitreous fluids from patients with diabetic retinopathy. Curr Eye Res 1996; 15: 1117-1123.
43. Jenkins AJ, Zhang SX, Rowley KG, et al. Increased serum pigment epithelium-derived factor is associated with microvascular complications, vascular stiffness and inflammation in Type 1 diabetes. Diabet Med 2007; 24: 1345-1351.
44. Matsuyama K, Ogata N, Matsuoka M, et al. Relationship between pigment epithelium-derived factor (PEDF) and renal function in patients with diabetic retinopathy. Mol Vis 2008; 14: 992-996.
45. Spranger J, Osterhoff M, Reimann M, et al. Loss of antiangiogenic pigment epithelium-derived factor in patients with angiogenic eye diseases. Diabetes 2001; 50: 2641-2645.
46. Ogata N, Nishikawa M, Nishimura T, Mitsuma Y, Matsumura M,. Unbalanced vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor in diabetic retinopathy. Am J Ophthalmol 2002; 134: 348-353.
47. Tombran-Tink J, Barnstable CJ,. PEDF: A multifaceted neurotrophic factor. Nat Rev Neurosci 2003; 4: 628-636.
48. Zhang SX, Wang JJ, Gao G, Shao C, Mott R, Ma JX,. Pigment epithelium-derived factor (PEDF) is an endogenous antiinflammatory factor. FASEB J 2006; 20: 323-325.
49. Thongboonkerd V, Malasit P,. Renal and urinary proteomics: Current applications and challenges. Proteomics 2005; 5: 1033-1042.
50. Chen LM, Song Q, Chao L, Chao J,. Cellular localization of tissue kallikrein and kallistatin mRNAs in human kidney. Kidney Int 1995; 48: 690-697.
51. Shen B, Hagiwara M, Yao YY, Chao L, Chao J,. Salutary effect of kallistatin in salt-induced renal injury, inflammation, and fibrosis via antioxidative stress. Hypertension 2008; 51: 1358-1365.
52. Chao J, Bledsoe G, Yin H, Chao L,. The tissue kallikrein-kinin system protects against cardiovascular and renal diseases and ischemic stroke independently of blood pressure reduction. Biol Chem 2006; 387: 665-675.
53. Chao J, Yin H, Yao YY, Shen B, Smith RS Jr, Chao L,. Novel role of kallistatin in protection against myocardial ischemia-reperfusion injury by preventing apoptosis and inflammation. Hum Gene Ther 2006; 17: 1201-1213.
54. Wang CR, Chen SY, Shiau AL, et al. Upregulation of kallistatin expression in rheumatoid joints. J Rheumatol 2007; 34: 2171-2176.
55. Wang CR, Chen SY, Wu CL, et al. Prophylactic adenovirus-mediated human kallistatin gene therapy suppresses rat arthritis by inhibiting angiogenesis and inflammation. Arthritis Rheum 2005; 52: 1319-1324.
56. Bläckberg M, Berling R, Ohlsson K,. Tissue kallikrein in severe acute pancreatitis in patients treated with high-dose intraperitoneal aprotinin. Pancreas 1999; 19: 325-334.